Kolexia
Reymond Maud Gastro-entérologie
Reymond Maud
Gastro-entérologie
Clinique De La Plaine
Clermont-Ferrand, France
51 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladie de Crohn Maladies inflammatoires intestinales Colite Nécrose Cirrhose du foie Fibrose Rectocolite hémorragique Hypertension artérielle Thrombophilie

Collaborateurs

Voir plus
Buisson Anthony
Buisson Anthony
Hôpital Estaing, Clermont-Ferrand, France
Manlay Luc
Manlay Luc
Centre Medico Chirurgical Tronquieres, Aurillac, France
Teilhet Camille
Teilhet Camille
Clinique De La Plaine, Clermont-Ferrand, France
Dapoigny Michel
Dapoigny Michel
Hôpital Estaing, Clermont-Ferrand, France

Industries

Voir plus
B3TSI
23 collaboration(s)
Dernière en 2022
Janssen
12 collaboration(s)
Dernière en 2023
A+A
8 collaboration(s)
Dernière en 2023
Abbvie
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Top-down Versus Step-up Strategies to Prevent Postoperative Recurrence in Crohn's Disease.
Inflammatory bowel diseases   02 février 2023
EXERCISE: Ex Vivo Study of the Role of Soluble Endothelial Protein C Receptor in Cirrhosis-associated Hypercoagulability State
Essai Clinique (CHU Clermont-Ferrand)   29 août 2022
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association   17 août 2022
P348 Top down versus step-up strategies to prevent postoperative recurrence in Crohn’s disease
Abstracts of the 17th Congress of ECCO Virtual February 16-19, 2022   21 janvier 2022
P400 Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
Abstracts of the 17th Congress of ECCO Virtual February 16-19, 2022   21 janvier 2022
Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy.
Journal of Crohn's & colitis   01 septembre 2021
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
Alimentary pharmacology & therapeutics   28 avril 2021
Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease.
Alimentary pharmacology & therapeutics   28 décembre 2020
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Liver international : official journal of the International Association for the Study of the Liver   01 juin 2020
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study.
Journal of Crohn's & colitis   24 février 2020